SBIR-STTR Award

Characterizing Alzheimer's Disease with INSPECDS: Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes
Award last edited on: 11/16/2017

Sponsored Program
SBIR
Awarding Agency
NIH : NIA
Total Award Amount
$1,086,648
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Chris Berka

Company Information

Advanced Brain Monitoring Inc (AKA: ABM~B-Alert)

2237 Faraday Avenue Suite 100
Carlsbad, CA 92008
   (760) 720-0099
   N/A
   www.b-alert.com
Location: Multiple
Congr. District: 49
County: San Diego

Phase I

Contract Number: N/A
Start Date: 7/15/2017    Completed: 4/30/2019
Phase I year
2017
Phase I Amount
$1
Direct to Phase II

Phase II

Contract Number: 1R44AG054256-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2017
(last award dollars: 2018)
Phase II Amount
$1,086,647

It is estimated that Alzheimer's and other neurodegenerative diseases causing dementia will surpass cancer as the leading cause of death by the year 2040. Alzheimer's is the leading cause of dementia, followed by synucleinopathies, including dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD), Fronto-temporal dementia and Vascular dementia. Among clinical researchers focused on investigating the varying etiologies, genetic associations, biomarkers, and treatment options for Alzheimer's disease, there is an urgent need for effective tools to aid in the classification of dementia subtypes, in the earliest detectable stages of the pathophysiological process. To address this unmet need Advanced Brain Monitoring (ABM) proposes to leverage day and night assessment technologies to create an Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes (INSPECDS) to profile Alzheimer's and other dementias. The core components of the INSPECDS platform will be the Alertness and Memory Profiler (AMP), the Sleep Profiler, and integrated machine-learning, classification algorithms, hosted on a secure, cloud-based, infrastructure for automated data processing, analysis, and reporting. The AMP was developed and validated intially for the purpose of detecting the neurocognitive effects of sleep deprivation in adults diagnosed with obstructive sleep apnea but has more recently been applied to assess Alzheimer's and Parkinson's disease. The AMP is unique among neurocognitive testing platforms in that it is the only one which integrates advanced, electrophysiological measures (e.g., 24-channel, wireless EEG and ECG) during the performance of computerized neurocognitive tasks and has proven effective in characterizing cognitive decline in Alzheimer's. This advanced capability permits researchers to explore real- time relations between fluctuations in alertness, discrete cognitive functions, and specific neural processes believed to subserve observed performance deficits in Alzheimer's and other dementias. The Sleep Profiler is an FDA-cleared, easily applied, wireless-EEG device that was developed and validated to measure sleep architecture for in-home sleep studies with submental (chin) EMG and wireless accelerometers to monitor head and limb movements to quantify the characteristics of REM-sleep behavior disorder (RBD), considered to be a prodromal expression of synucleinopathy. Furthermore, the application of sophisticated, machine- learning, classification algorithms will streamline the processing and analyses of these data to derive statistical probabilities of Alzheimer's and other dementia subtypes. The overarching goal of the current, Direct-to-Phase II, SBIR project is to finalize implementation of a secure, cloud-based infrastructure to compile the data obtained from the AMP and Sleep Profiler, train classification algorithms to discriminate among Alzheimer's and other dementia subtypes, validate diagnostic accuracy, and integrate optimized classifiers within the cloud- based architecture. Once completed, the INSPECDS system will be the first clinical research tool of its kind and find immediate application in both university-based research settings and pharmaceutical industry clinical trials to aid in the endophenotypic stratification of Alzheimer's and other dementias.

Public Health Relevance Statement:
PROJECT NARRATIVE Among clinical researchers focused on investigating the varying etiologies, genetic associations, clinical course, and treatment options for Alzheimer's and other neurodengenerative diseases, there is an urgent need for effective tools to aid in the classification of dementia subtypes, in the earliest detectable stages of the pathophysiological process. To address this unmet need, Advanced Brain Monitoring (Carlsbad, CA) is developing Integrated Neurocognitive and Sleep-Behavior Profilers for the Endophenotypic Classification of Dementia Subtypes (INSPECDS), which will provide an inexpensive, non-invasive solution combining neurocognitive, electrophysiological (EEG, ECG, EMG), and sleep-behavior assessment into a single, integrated system featuring automated scoring and classification algorithms. Once completed, the INSPECDS system will be the first clinical tool of its kind and find immediate application in clinical settings and pharmaceutical industry clinical trials to aid in the endophenotypic stratification of Alzheimer's and other dementia patients.

Project Terms:
Accelerometer; Address; Adult; alertness; Algorithms; Alzheimer's Disease; Architecture; Automatic Data Processing; base; Behavior; Behavior assessment; Biological Markers; Blinded; Brain; brain behavior; California; Cardiovascular Diseases; Cause of Death; Characteristics; Chin; Classification; Clinic; Clinical; Clinical Research; Clinical Trials; cloud based; cognitive function; cohort; computerized; Data; data acquisition; Data Analyses; Databases; Dementia; Depressed mood; Devices; Diagnosis; diagnostic accuracy; Disease; Disease Progression; Drug Industry; Economic Burden; Elderly; Electrocardiogram; Electroencephalography; Electrophysiology (science); Enrollment; Etiology; Frontotemporal Dementia; Funding; General Hospitals; genetic association; Goals; Head Movements; Home environment; human subject; Impaired cognition; Individual; Lewy Body Dementia; limb movement; Machine Learning; Malignant Neoplasms; Massachusetts; Measures; Memory; mild cognitive impairment; Minor; Modification; Monitor; Neurocognitive; neurocognitive test; Neurodegenerative Disorders; Neurologic; Neuropsychological Tests; Obstructive Sleep Apnea; Parkinson Disease; Parkinson's Dementia; Patients; Performance; Phase; Probability; Process; relating to nervous system; REM Sleep Behavior Disorder; Reporting; Research; Research Infrastructure; Research Personnel; Sampling; Secure; Sleep; Sleep Architecture; Sleep Deprivation; Small Business Innovation Research Grant; Stratification; stroke; Study Subject; synucleinopathy; System; Technology; Technology Assessment; Testing; Time; tool; Training; United States National Institutes of Health; Universities; Vascular Dementia; Wireless Technology